BIOCON AFTER THE BUILD-OUT: WHEN AMBITION MEETS ECONOMICS
(This is a follow up to the earlier blog on Biocon Ltd., where we explored the company’s biologics strategy and India’s gradual shift toward complex therapies. With FY26 developments and recent management commentary now available, this piece revisits that evolving thesis.) THE CONVERSATION AROUND BIOCON IS CHANGING For years, the Biocon story was largely about […]